Leta i den här bloggen


lördag 5 maj 2018

INTERLEUKIINI-33 (Kr.9p24.1,NF-HEV, NFEHEV, IL1F1L

https://www.ncbi.nlm.nih.gov/gene/90865
/note="DVS27-related protein;
 nuclear factor for high  endothelial venules;
 nuclear factor from high endothelial venules; 
interleukin-1 family member 11"
Also known as
DVS27; IL1F11; NF-HEV; NFEHEV; C9orf26
Summary
The protein encoded by this gene is a cytokine that binds to the IL1RL1/ST2 receptor. The encoded protein is involved in the maturation of Th2 cells and the activation of mast cells, basophils, eosinophils and natural killer cells. Several transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Sep 2015]
Expression
Ubiquitous expression in urinary bladder (RPKM 34.7), lung (RPKM 27.3) and 23 other tissues See more
 Study identify that IL-33 expression is reduced in many carcinomas upon their transition to the metastatic form of disease and, appears to be directly correlated with MHC-I and possibly co-regulated. These results suggest that the down-regulation of IL-33 takes place concomitantly with the transition from primary to metastatic tumors and represents an entirely new form of tumor immune-escape.
A new paradigm for understanding immune-surveillance and immune escape in cancer is described here. Metastatic carcinomas express reduced levels of IL-33 and diminished levels of antigen processing machinery (APM), compared to syngeneic primary tumours. Complementation of IL-33 expression in metastatic tumours upregulates APM expression and functionality of major histocompatibility complex (MHC)-molecules, resulting in reduced tumour growth rates and a lower frequency of circulating tumour cells. Parallel studies in humans demonstrate that low tumour expression of IL-33 is an immune biomarker associated with recurrent prostate and kidney renal clear cell carcinomas. Thus, IL-33 has a significant role in cancer immune-surveillance against primary tumours, which is lost during the metastatic transition that actuates immune escape in cancer.

  • Artikkeleita PubMed
  • Interleukiini-33 signalointitien kartta (2018) 

 https://www.ncbi.nlm.nih.gov/pubmed/29705949
A network map of IL-33 signaling pathway.
Interleukin-33 (IL-33) is a member of the IL-1 family of cytokines that play a central role in the regulation of immune responses. Its release from epithelial and endothelial cells is mediated by pro-inflammatory cytokines, cell damage and by recognition of pathogen-associated molecular patterns (PAMPs). The activity of IL-33 is mediated by binding to the IL-33 receptor complex (IL-33R) and activation of NF-κB signaling via the classical MyD88/IRAK/TRAF6 module. IL-33 also induces the phosphorylation and activation of ERK1/2, JNK, p38 and PI3K/AKT signaling modules resulting in the production and release of pro-inflammatory cytokines. Aberrant signaling by IL-33 has been implicated in the pathogenesis of several acute and chronic inflammatory diseases, including asthma, atopic dermatitis, rheumatoid arthritis and ulcerative colitis among others. Considering the biomedical importance of IL-33, we developed a pathway resource of signaling events mediated by IL-33/IL-33R in this study. Using data mined from the published literature, we describe an integrated pathway reaction map of IL-33/IL-33R consisting of 681 proteins and 765 reactions. These include information pertaining to 19 physical interaction events, 740 enzyme catalysis events, 6 protein translocation events, 4 activation/inhibition events, 9 transcriptional regulators and 2492 gene regulation events. The pathway map is publicly available through NetPath ( http://www.netpath.org /), a resource of human signaling pathways developed previously by our group. This resource will provide a platform to the scientific community in facilitating identification of novel therapeutic targets for diseases associated with dysregulated IL-33 signaling. Database URL: http://www.netpath.org/pathways?path_id=NetPath_120

KEYWORDS:

Immune response; Inflammation; NetSlim; Post-translational modifications; Pro-inflammatory cytokine; Protein-protein interactions
PMID:
29705949
DOI:
10.1007/s12079-018-0464-4

Tietoa Interleukiinsita IL-33 Pubmed hakulaiteella

Preferred Names
interleukin-33
Names
DVS27-related protein
interleukin-1 family member 11
nuclear factor for high endothelial venules
nuclear factor from high endothelial venules
Conserved Domains (1) summary  pfam15095
Location:5226 IL33; Interleukin 33
interleukin-33 isoform b [Homo sapiens]
NCBI Reference Sequence: NP_001186569.1 
Identical Proteins FASTA Graphics
Go to:
LOCUS       NP_001186569             228 aa            linear   PRI 05-APR-2018
DEFINITION  interleukin-33 isoform b [Homo sapiens].
ACCESSION   NP_001186569
VERSION     NP_001186569.1
DBSOURCE    REFSEQ: accession NM_001199640.1
KEYWORDS    RefSeq.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
            Catarrhini; Hominidae; Homo.
REFERENCE   1  (residues 1 to 228)
  AUTHORS   Xu Z, Zhao C, Wang Z, Tao J, Han Z, Zhang W, Tan R and Gu M.
  TITLE     Interleukin-33 levels are elevated in chronic allograft dysfunction
            of kidney transplant recipients and promotes epithelial to
            mesenchymal transition of human kidney (HK-2) cells
  JOURNAL   Gene 644, 113-121 (2018)
   PUBMED   29122645
  REMARK    GeneRIF: IL-33 could induce EMT.
REFERENCE   2  (residues 1 to 228)
  AUTHORS   Umebashi K, Tokito A, Yamamoto M and Jougasaki M.
  TITLE     Interleukin-33 induces interleukin-8 expression via JNK/c-Jun/AP-1
            pathway in human umbilical vein endothelial cells
  JOURNAL   PLoS ONE 13 (1), e0191659 (2018)
   PUBMED   29373608
  REMARK    GeneRIF: IL-33 induces IL-8 expression via JNK/c-Jun/AP-1 pathway
            in human vascular endothelial cells, and provides a new insight
            into the role of IL-33-induced IL-8 in the pathophysiology of
            atherosclerosis and vascular inflammation
            Publication Status: Online-Only
REFERENCE   3  (residues 1 to 228)
  AUTHORS   Yamamoto M, Umebashi K, Tokito A, Imamura J and Jougasaki M.
  TITLE     Interleukin-33 induces growth-regulated oncogene-alpha expression
            and secretion in human umbilical vein endothelial cells
  JOURNAL   Am. J. Physiol. Regul. Integr. Comp. Physiol. 313 (3), R272-R279
            (2017)
   PUBMED   28637660
  REMARK    GeneRIF: Taken together, the present study indicates that IL-33
            localized in the human atherosclerotic plaque increases GRO-alpha
            mRNA expression and protein secretion via activation of ERK1/2,
            JNK, and NF-kappaB in HUVECs, suggesting that IL-33 plays an
            important role in the pathophysiology and development of
            atherosclerosis.
REFERENCE   4  (residues 1 to 228)
  AUTHORS   Ndaw VS, Abebayehu D, Spence AJ, Paez PA, Kolawole EM, Taruselli
            MT, Caslin HL, Chumanevich AP, Paranjape A, Baker B, Barnstein BO,
            Haque TT, Kiwanuka KN, Oskeritzian CA and Ryan JJ.
  TITLE     TGF-beta1 Suppresses IL-33-Induced Mast Cell Function
  JOURNAL   J. Immunol. 199 (3), 866-873 (2017)
   PUBMED   28637902
  REMARK    GeneRIF: TGF-beta1 also suppressed the combined effects of IL-33
            and IgE-mediated activation on mouse and human mast cells. The role
            of IL-33 in the pathogenesis of allergic diseases is incompletely
            understood. These findings, demonstrate that TGF-beta1 can provide
            broad inhibitory signals to activated mast cells.
REFERENCE   5  (residues 1 to 228)
  AUTHORS   Lock FE, Babaian A, Zhang Y, Gagnier L, Kuah S, Weberling A, Karimi
            MM and Mager DL.
  TITLE     A novel isoform of IL-33 revealed by screening for transposable
            element promoted genes in human colorectal cancer
  JOURNAL   PLoS ONE 12 (7), e0180659 (2017)
   PUBMED   28715472
  REMARK    GeneRIF: LTR-IL-33 expression is required for optimal CRC cell line
            growth
            Publication Status: Online-Only
REFERENCE   6  (residues 1 to 228)
  AUTHORS   Tada H, Shimizu T, Matsushita K and Takada H.
  TITLE     Porphyromonas gingivalis-induced IL-33 down-regulates hCAP-18/LL-37
            production in human gingival epithelial cells
  JOURNAL   Biomed. Res. 38 (3), 167-173 (2017)
   PUBMED   28637951
  REMARK    GeneRIF: IL-33 down-regulates the induction of hCAP-18/LL-37
            production in human gingival epithelial cells.
REFERENCE   7  (residues 1 to 228)
  AUTHORS   Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK,
            Zurawski G, Moshrefi M, Qin J, Li X, Gorman DM, Bazan JF and
            Kastelein RA.
  TITLE     IL-33, an interleukin-1-like cytokine that signals via the IL-1
            receptor-related protein ST2 and induces T helper type 2-associated
            cytokines
  JOURNAL   Immunity 23 (5), 479-490 (2005)
   PUBMED   16286016
  REMARK    GeneRIF: IL-33, which mediates its biological effects via IL-1
            receptor ST 2, activates NF-kappaB and MAP kinases, and drives
            production of T(H)2-associated cytokines from in vitro polarized
            T(H)2 cells
REFERENCE   8  (residues 1 to 228)
  AUTHORS   Humphray SJ, Oliver K, Hunt AR, Plumb RW, Loveland JE, Howe KL,
            Andrews TD, Searle S, Hunt SE, Scott CE, Jones MC, Ainscough R,
            Almeida JP, Ambrose KD, Ashwell RI, Babbage AK, Babbage S, Bagguley
            CL, Bailey J, Banerjee R, Barker DJ, Barlow KF, Bates K, Beasley H,
            Beasley O, Bird CP, Bray-Allen S, Brown AJ, Brown JY, Burford D,
            Burrill W, Burton J, Carder C, Carter NP, Chapman JC, Chen Y,
            Clarke G, Clark SY, Clee CM, Clegg S, Collier RE, Corby N, Crosier
            M, Cummings AT, Davies J, Dhami P, Dunn M, Dutta I, Dyer LW,
            Earthrowl ME, Faulkner L, Fleming CJ, Frankish A, Frankland JA,
            French L, Fricker DG, Garner P, Garnett J, Ghori J, Gilbert JG,
            Glison C, Grafham DV, Gribble S, Griffiths C, Griffiths-Jones S,
            Grocock R, Guy J, Hall RE, Hammond S, Harley JL, Harrison ES, Hart
            EA, Heath PD, Henderson CD, Hopkins BL, Howard PJ, Howden PJ,
            Huckle E, Johnson C, Johnson D, Joy AA, Kay M, Keenan S, Kershaw
            JK, Kimberley AM, King A, Knights A, Laird GK, Langford C, Lawlor
            S, Leongamornlert DA, Leversha M, Lloyd C, Lloyd DM, Lovell J,
            Martin S, Mashreghi-Mohammadi M, Matthews L, McLaren S, McLay KE,
            McMurray A, Milne S, Nickerson T, Nisbett J, Nordsiek G, Pearce AV,
            Peck AI, Porter KM, Pandian R, Pelan S, Phillimore B, Povey S,
            Ramsey Y, Rand V, Scharfe M, Sehra HK, Shownkeen R, Sims SK, Skuce
            CD, Smith M, Steward CA, Swarbreck D, Sycamore N, Tester J, Thorpe
            A, Tracey A, Tromans A, Thomas DW, Wall M, Wallis JM, West AP,
            Whitehead SL, Willey DL, Williams SA, Wilming L, Wray PW, Young L,
            Ashurst JL, Coulson A, Blocker H, Durbin R, Sulston JE, Hubbard T,
            Jackson MJ, Bentley DR, Beck S, Rogers J and Dunham I.
  TITLE     DNA sequence and analysis of human chromosome 9
  JOURNAL   Nature 429 (6990), 369-374 (2004)
   PUBMED   15164053
REFERENCE   9  (residues 1 to 228)
  AUTHORS   Baekkevold ES, Roussigne M, Yamanaka T, Johansen FE, Jahnsen FL,
            Amalric F, Brandtzaeg P, Erard M, Haraldsen G and Girard JP.
  TITLE     Molecular characterization of NF-HEV, a nuclear factor
            preferentially expressed in human high endothelial venules
  JOURNAL   Am. J. Pathol. 163 (1), 69-79 (2003)
   PUBMED   12819012
  REMARK    GeneRIF: Results suggest that NF-HEV may be one of the key nuclear
            factors that controls the specialized phenotype of the lymphatic
            venule endothelium.
REFERENCE   10 (residues 1 to 228)
  AUTHORS   Onda H, Kasuya H, Takakura K, Hori T, Imaizumi T, Takeuchi T, Inoue
            I and Takeda J.
  TITLE     Identification of genes differentially expressed in canine
            vasospastic cerebral arteries after subarachnoid hemorrhage
  JOURNAL   J. Cereb. Blood Flow Metab. 19 (11), 1279-1288 (1999)
   PUBMED   10566975
COMMENT     REVIEWED REFSEQ: This record has been curated by NCBI staff. The
            reference sequence was derived from DB477860.1, AK303943.1,
            BC047085.1, AB024518.1 and AI610794.1.
            
            Summary: The protein encoded by this gene is a cytokine that binds
            to the IL1RL1/ST2 receptor. The encoded protein is involved in the
            maturation of Th2 cells and the activation of mast cells,
            basophils, eosinophils and natural killer cells. Several transcript
            variants encoding different isoforms have been found for this gene.
            [provided by RefSeq, Sep 2015].
            
            Transcript Variant: This variant (2) lacks an alternate in-frame
            exon compared to variant 1. The resulting isoform (b, also known as
            2) has the same N- and C-termini but is shorter compared to isoform
            a.
            
            Publication Note:  This RefSeq record includes a subset of the
            publications that are available for this gene. Please see the Gene
            record to access additional publications.
            
            ##Evidence-Data-START##
            Transcript exon combination :: SRR1803616.212850.1, AK303943.1
                                           [ECO:0000332]
            RNAseq introns              :: single sample supports all introns
                                           SAMEA1968540, SAMEA1968968
                                           [ECO:0000348]
            ##Evidence-Data-END##
FEATURES             Location/Qualifiers
     source          1..228
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
                     /chromosome="9"
                     /map="9p24.1"
     Protein         1..228
                     /product="interleukin-33 isoform b"
                     /note="DVS27-related protein; nuclear factor for high
                     endothelial venules; nuclear factor from high endothelial
                     venules; interleukin-1 family member 11"
                     /calculated_mol_wt=25799
     Region          5..226
                     /region_name="IL33"
                     /note="Interleukin 33; pfam15095"
                     /db_xref="CDD:317507"
     CDS             1..228
                     /gene="IL33"
                     /gene_synonym="C9orf26; DVS27; IL1F11; NF-HEV; NFEHEV"
                     /coded_by="NM_001199640.1:79..765"
                     /note="isoform b is encoded by transcript variant 2"
                     /db_xref="CCDS:CCDS56563.1"
                     /db_xref="GeneID:90865"
                     /db_xref="HGNC:HGNC:16028"
                     /db_xref="MIM:608678"
ORIGIN      
        1 mkpkmkystn kistakwknt askalcfklg ksqqkakevc pmyfmklrsg lmikkeacyf
       61 rrettkrpsl ktgrkhkrhl vlaacqqqst vecfafgisg vqkytralhd ssitdkvlls
      121 yyesqhpsne sgdgvdgkml mvtlsptkdf wlhannkehs velhkcekpl pdqaffvlhn
      181 mhsncvsfec ktdpgvfigv kdnhlalikv dssenlcten ilfklset
//

Inga kommentarer:

Skicka en kommentar